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Abstract
Objective: Single voxel proton magnetic resonance spectroscopy (MRS) can be used to monitor changes in brain
inflammation and neuronal integrity associated with HIV infection and its treatments. We used MRS to measure brain
changes during the first weeks following HIV infection and in response to antiretroviral therapy (ART).
Methods: Brain metabolite levels of N-acetyl aspartate (NAA), choline (tCHO), creatine (CR), myoinositol (MI), and glutamate
and glutamine (GLX) were measured in acute HIV subjects (n=31) and compared to chronic HIV+individuals (n=26) and HIV
negative control subjects (n=10) from Bangkok, Thailand. Metabolites were measured in frontal gray matter (FGM), frontal
white matter (FWM), occipital gray matter (OGM), and basal ganglia (BG). Repeat measures were obtained in 17 acute
subjects 1, 3 and 6 months following initiation of ART.
Results: After adjustment for age we identified elevated BG tCHO/CR in acute HIV cases at baseline (median 14 days after
HIV infection) compared to control (p=0.0014), as well as chronic subjects (p=0.0023). A similar tCHO/CR elevation was
noted in OGM; no other metabolite abnormalities were seen between acute and control subjects. Mixed longitudinal
models revealed resolution of BG tCHO/CR elevation after ART (p=0.022) with tCHO/CR similar to control subjects at 6
months.
Interpretation: We detected cellular inflammation in the absence of measurable neuronal injury within the first month of
HIV infection, and normalization of this inflammation following acutely administered ART. Our findings suggest that early
ART may be neuroprotective in HIV infection by mitigating processes leading to CNS injury.
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Introduction
Infection with human immunodeficiency virus-1 (HIV) remains
a major health issue affecting 34 million people worldwide, with
2.7 million new infections reported in 2010 [1]. HIV enters the
central nervous system (CNS) within days of initial exposure, based
on limited reports in humans and studies from animal models
employing simian immunodeficiency virus (SIV) [2,3]. Lacking the
CD4+cell surface receptor, neurons are not appreciably infected
by HIV. Rather, an inflammatory response ensues, involving
microglial cells and perivascular macrophages and leading to
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e49272neuronal dysfunction and, ultimately, neuronal loss [4]. Limited
human studies completed within the first year of infection
(‘‘primary’’ rather than ‘‘acute’’ infection) suggest early CNS
involvement [5,6]. The extent and timing of CNS invasion is not
precisely known in humans, but is increasingly important as the
field focuses on HIV eradication strategies that require a clear
understanding of when viral reservoirs are established and how
early intervention may impact these reservoirs. Strategies to
address chronic complications of HIV may also be informed by
understanding the timing and characteristics of early CNS
involvement.
Infection and inflammation of the CNS is linked to neurological
and cognitive findings in chronic HIV. Cerebrospinal fluid (CSF)
HIV RNA levels are more valuable in predicting neuropsycho-
logical testing impairment 6 months following initiation of ART
than are plasma HIV RNA levels, CD4+lymphocyte counts, or
Centers for Disease Control and Prevention disease stage
classification [7]. Despite suppressive ART, many patients
experience mild deficits of cognitive and motor ability that impact
function in later stages of infection [8]. The extent to which events
of acute HIV influence long-term consequences in the CNS is
incompletely understood.
Non-invasive
1H-proton magnetic resonance spectroscopy
(MRS) measures signals from hydrogen atoms specific to the
molecular structure of the metabolite in which they are contained.
Brain MRS studies can document the extent of inflammation
underlying HIV, disease progression and treatment response.
Neurons can be distinguished by the relative level of N-acetyl-
aspartate (NAA), because it is synthesized within the brain almost
exclusively by neurons from aspartate and acetyl coenzyme A [9].
Decreased NAA is noted in association with HIV-associated
dementia (HAD), cognitive impairment, neurological symptoms
and among medically asymptomatic HIV+individuals [10,11,12].
Increased myoinositol (MI) is observed in HIV dementia and
thought to represent gliosis, whereas increased total choline
(tCHO) in this setting is thought to represent infiltration of
inflammatory cells [13,14]. Glutamate (GLU), a major brain
excitatory neurotransmitter, is associated with HIV-induced
neurotoxicity where excessive activation of N-methyl-D-aspartate
receptors results in increased extracellular glutamate and neuronal
cell death [15,16]. At 1.5 tesla magnet strength, glutamate cannot
be confidently partitioned from glutamine (GLN) and is combined
for analyses (GLX).
The primary goal for this study was to examine brain MRS
metabolites during the first month of HIV infection. We sought to
define the extent of brain parenchymal inflammation and
neuronal injury and to examine changes in these metabolites after
initiation of ART during acute HIV.
Subjects and Methods
Patient Selection
This study investigated the first 40 enrollees of the RV 254/
SEARCH 010 protocol, an ongoing study characterizing acute
HIV infection in Bangkok, Thailand (clinicalTrials.gov #
NCT00796146 and NCT00796263). All cases were enrolled
during Fiebig stages I-IV, the earliest stage of HIV infection before
appreciable antibody response can be detected and typically less
than one month after exposure. Details are provided elsewhere
[3,17]. Briefly, all cases were identified from two facilities in
Bangkok, Thailand and were age 18 years or older. Although
exclusion criteria included major medical or psychiatric disorders
that could potentially impact cognition, there were no individuals
meeting these exclusion criteria. Among the first 40 enrollees, 8
were not evaluated in the MRS portion of the study due to
conversion to Fiebig V before enrollment (n=4) presence of
metallic dental braces (n=2), claustrophobia (n=1) or no consent
to MRS (n=1). Additionally, one case was later excluded due to
presumed neurosyphilis.
Immediately after enrollment and baseline MRI/MRS, 29/31
participants started ART composed of efavirenz (EFV), tenofovir
(TNF), and emtricitabine (FTC) (standard ART). Eighteen of these
subjects also started raltegravir (RAL) and maraviroc (MRC)
(‘‘mega-ART’’). Efavirenz was discontinued in 9 cases due to
intolerance (n=7) or primary drug resistance (n=2). Among
these, only two cases were on standard ART, and the efavirenz
was replaced with raltegravir. Seventeen subjects who completed
all follow-up MRS (months 1, 3, and 6) were evaluated to
investigate treatment response.
Ethics Statement
The studies were approved by institutional review boards in
Thailand (Chulalongkorn University Hospital, FWA00000943,
IRB00001607) and in the U.S. (University of California, San
Francisco, FWA00000068; and the Walter Reed Army Institute of
Research, Rockville, MD, FWA00000015). All participants signed
written consent.
Chronic HIV-infected and HIV-negative Control Groups
Twenty-six ART-naı ¨ve chronically infected HIV+Thai subjects
(participating in one of two studies: clinicalTrials.gov #
NCT00782808 or NCT00777426) and 10 HIV-negative Thai
controls (screened by a trained clinician to be ‘healthy’) were
analyzed for comparison. All controls and chronically infected
subjects were deemed to have normal cognition after neuropsy-
chological testing and multi-disciplinary consensus conferences,
which included a neurologist and a neuropsychologist, met the
same exclusion criteria as the acute subjects, and were free of
opportunistic infection. All subjects underwent one-time (baseline)
MRS using the same protocol on the same scanner with no interim
software or hardware upgrades and captured by the same
technician (MP).
Clinical Parameters
Lymphocyte subsets were measured at a local clinical laboratory
and plasma HIV RNA levels were measured in fresh specimens by
Roche Amplicor HIV-1 Monitor Test v1.5 with dilution for HIV
RNA.750,000 copies/ml.
Imaging Acquisition and Quality Control
Subjects underwent an axial 3D T1-weighted spoiled gradient
echo image (3D SPGR, TE=7 ms, TR=11.2 ms, flip an-
gle=25
o, with 1 mm voxel resolution) MRI scan on a GE Signa
HDx 1.5T clinical scanner (GE Healthcare, Milwaukee, WI,
software version 12-M4) using an 8-channel head coil for data
reception and a standard body coil for transmission. Single voxel
MRS was acquired using a double spin echo data acquisition
(PROBE-P) with TE=35 ms, TR=1.5s at four voxel locations:
left frontal white matter (FWM, 8cc), midline frontal grey matter
(FGM, 8cc), occipital grey matter (OGM, 8cc) and basal ganglia
(BG, 12cc, Figure 1). A total of 16 unsuppressed water free
induction decays (FIDs) and 128 water suppressed FIDs were
acquired for all voxels, with 192 water suppressed FIDs acquired
at BG. To ensure scanner stability, short echo-time (TE=35 ms)
single voxel MRS measurements using a standard spectroscopy
phantom (GE Healthcare) were performed at the conclusion of
each subject examination [18].
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Data were transferred by secured protocol to the central
processing location at Huntington Medical Research Institutes in
Pasadena, CA where two authors (NS and WR) processed all data
using the time domain linear combination fitting software,
LCModel (version 6.2, http://s-provencher.com/pages/lcmodel.
shtml). Briefly, time domain MRS data from each coil of the 8-
channel phased array head coil were combined using unsup-
pressed water FIDs from each coil as scaling factor [19]. The FIDs
were processed without spectral line broadening for fitting. Fittings
were performed between 4.0-0.5 ppm, using a reference basis set
acquired using the same data acquisition parameters as in vivo. The
reference solutions were 50 mM NAA, 50 mM CHO, 100 mM
GLU, 100 mM GLN, 100 mM CR, and 150 mM MI. All
reference solutions were adjusted to pH 7.2 with 0.1 M NaOH.
Metabolite quantification for NAA, CR, tCHO, MI, and GLX
were included only if the signal to noise ratio was.4 and their
percent standard deviations were,20% [20].
Statistical Analysis
Baseline characteristics between groups were compared using
analysis of variance (ANOVA) and Tukey procedure for pairwise
comparisons. We analyzed the main effect of acute and chronic
HIV on metabolites using general linear model multivariate
analyses of variance (MANOVA). We completed multivariate
analyses using Pillai’s Trace tests for each voxel including the three
groups as predictors and the four metabolites of interest (NAA,
MI, CHO, GLX) as responses. For voxels where we rejected the
joint null hypothesis of no effect of acute, chronic and control
groups on the responses at p=0.05, we then examined the
individual metabolite levels within those models. Voxels for which
we did not reject the null hypothesis were not investigated further.
For voxels for which the null hypotheses were rejected, further
analyses compared the metabolites among the different groups
using ANOVA. In all models, CR and age were included as
covariates. Although mean educational attainment and gender
differed among groups, they were not included in the primary
models since our main analyses compared acute cases to controls
and since age and CR were more important to covary than was
education and gender, each was felt less likely to appreciably
impact MRS. Secondary analyses included education.
For the acute HIV+group, we used Spearman’s correlation to
evaluate the relationship between MRS data and clinical variables.
We evaluated MRS changes over time using mixed models with a
complete case analysis approach. The 6-month metabolite ratios
were compared to the cross-sectional HIV-negative control ratios
to assess for normalization of values associated with treatment.
Results
Clinical Composition
The 31 acute HIV+subjects were at Fiebig stages I (10); II (3);
III (15); and IV (3) at the time of MRS with a median (range)
estimated duration since exposure of 14 (1–32) days (Table 1).
Individuals tended to be young men who have sex with men
(MSM) and no subjects reported injection drug use. In cases that
provided information, 14 subjects denied illicit drugs for at least
four months prior to enrollment, two were active users of
methamphetamine, and nine were non-illicit drug users. The
median (range) CD4
+lymphocyte count and plasma HIV RNA
level were lower for the chronic HIV group (p,0.0001 and
p=0.014, respectively). The HIV subtypes were identified to be
CRF01_AE (n=25) and B (n=1) with 5 cases that could not be
typed.
Scanner Quality Assurance
A total of 133 MRI/MRS examinations were performed on 67
subjects over a period of 32 months (from December 2008 to May
2011). We observed low percent coefficient of variation of
phantom metabolite concentrations (Baseline: NAA/
CR=2.56%, CHO/CR=2.62%, MI/CR=3.33%, NAA/
MI=3.56%; 6 months: NAA/CR=2.60%, CHO/CR=2.65%,
MI/CR=3.40%, NAA/MI=3.70%) reflecting hardware stability
and an ability to reliably detect changes in metabolite ratios of 2–
4%.
Baseline Brain Metabolites
Our statistical approach identified voxels at BG (p=0.002) and
OGM (p=0.037) for further investigation (Table 2). In BG, we
identified increased tCHO/CR in acute compared to control
groups (0.249 vs. 0.227, p=0.001) and compared to chronic
groups (0.233, p=0.002). NAA/CR did not differ compared to
controls although it was higher than that measured in the chronic
group (1.134 vs. 1.000, p=0.005). In OGM, we similarly noted
elevated tCHO/CR in acute compared to control groups (0.176
vs. 0.153, p=0.001). We also identified higher GLX/CR in the
acute compared to chronic groups (1.980 vs. 1.763, p=0.004), but
no significant differences between GLX/CR in control subjects
and either HIV group. We did not include education in our
primary models due to the small sample size; however, repeated
analyses that included education did not appreciably alter these
Figure 1. MRS voxel locations. A) left frontal white matter; B) basal ganglia; C) midline frontal gray matter; D) occipital gray matter.
doi:10.1371/journal.pone.0049272.g001
MR Spectroscopy during Acute HIV Infection
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e49272findings. Voxels at FWM and FGM were not evaluated as they did
not meet scrutiny of our statistical approach. Secondary explora-
tions in these voxels did not suggest missed findings.
Multivariate models within the acute group identified a
relationship between CSF HIV RNA and metabolites in FWM
only. Examining individual metabolites at this voxel, we identified
a direct association between log10 CSF HIV RNA and GLX/CR
(b=0.193, p=0.002). We did not identify associations with
estimated duration of infection. Patients with Fiebig III/IV had
significantly increased BG NAA/CR after adjusting for age, as
compared to patients with Fiebig I/II (b=0.056, p=0.018). No
other correlations were identified in relation to Fiebig stage.
Metabolite Changes with ART
In longitudinal mixed models, we identified two categories of
change following treatment with ART. Decreased inflammatory
metabolites were noted with tCHO/CR at BG (b=20.002/
month, p=0.022) and MI/CR at OGM (b=20.009, p=0.029).
Table 1. Demographic characteristics of the investigated groups.
Results Acute (n=31) Chronic (n=26) Control (n=10) P-value
Gender 84% male 50% male 60% male 0.022
Age, yrs, mean (range) 30 (19–46) 34 (25–48) 36 (27–45) 0.0340
Education, yrs, mean (range) 16 (6–25) 11 (3–19) 16 (6–25) 0.0002
Risk category
1
-Homosexual 6 13 –
-Heterosexual – 1 –
-Bisexual 22 10 –
-Transfusion – 2 –
-Unknown 3 – –
Infection duration
2, days, median (range) 14.0 (1–32) ––
CD4 count, cells/mm3, median (range) 428 (132–1127) 215 (19–553) – ,.0001
Log10 plasma HIV RNA, median (range) 5.51 (2.78–7.41) 4.75 (3.22–5.88) – 0.0142
Log10 CSF HIV RNA, median (range)
3 3.39 (1.70–5.12) ––
1. Risk factors by self-report;
2. Self-reported days since estimated exposure at enrollment [when a range of dates was provided (multiple potential exposures) the mean was used]. For age, chronic
cases and controls do not differ, but each differ from mean of acute cases; for education, acute cases and controls do not differ, but each differ from chronic cases;
3. Data available on 24/31 cases.
doi:10.1371/journal.pone.0049272.t001
Table 2. Metabolites at BG and OGM, adjusting for Cr and age.
All (N=67) Acute (n=31) Chronic (n=26) Control (n=10) P-value
1 P-value
2 P-value
3
Mean SD Mean SD Mean SD Mean SD
Basal Ganglia
MI 0.574 0.12 0.580 0.13 0.560 0.12 0.589 0.09 0.449 0.898 0.689
NAA 1.073 0.15 1.134 0.14 1.000 0.14 1.077 0.13 0.005
0.0051
0.552 0.014
tCHO 0.239 0.02 0.249 0.02 0.233 0.02 0.227 0.01 0.002 0.001 0.001
GLX 1.880 0.29 1.963 0.34 1.807 0.23 1.812 0.22 0.062 0.290 0.146
Multivariate Statistics
Pillai’s Trace ,0.001 0.016 0.002
Occipital Gray Matter
MI 0.766 0.08 0.765 0.08 0.773 0.09 0.751 0.10 0.707 0.353 0.554
NAA 1.417 0.12 1.416 0.13 1.415 0.12 1.428 0.12 0.958 0.123 0.323
tCHO 0.170 0.02 0.176 0.02 0.168 0.02 0.153 0.02 0.162 0.001 0.015
GLX 1.875 0.28 1.980 0.21 1.763 0.34 1.841 0.23 0.004 0.052 ,0.001
Multivariate Statistics
Pillai’s Trace 0.069 0.041 0.035
1, p-value for comparison between acute and chronic HIV;
2. p-value for comparison between acute and control;
3. p-value for comparison among acute, chronic, and control groups.
doi:10.1371/journal.pone.0049272.t002
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p=0.038), FWM (b=0.018/month, p=0.032) and OGM
(b=0.021/month, p,0.001) longitudinally. Most of these changes
were temporally related to initiation of treatment with large
changes at month 1 and lesser changes thereafter (Figure 2). We
also noted two distinct groups of subjects relative to CHO/CR in
BG. Using Pearson correlations we investigated the relationship
between baseline CHO/CR and that at 1, 3, and 6 months
identifying the following correlation coefficients and p-values:
r=0.544, p=0.024; r=0.761, p,0.001; and r=0.449, p=0.070,
respectively, suggesting that individuals with higher values at
baseline tended to also have higher values at follow-up. The MRS
signature at six months following ART initiation did not differ
from that of controls, adjusting for age and comparing all
metabolites at each voxel.
Discussion
Findings from this study provide indirect evidence for inflam-
matory changes within brain parenchyma during the earliest
stages (median 14 days after HIV transmission) of HIV infection.
Our findings extend existing knowledge of brain involvement
through CSF analyses by demonstrating abnormalities within
brain tissue itself. In our work, the MRS inflammatory signature
normalized after ART that included medications with high (EFV,
MVC, RAL, FTC) CNS penetration-effectiveness, based on
cerebrospinal fluid studies. We noted no detectable differences
seen in comparison to control subjects. The metabolite primarily
altered was CHO, thought to reflect reactive cell turnover as it is
closely correlated to membrane lipids [21]. Our findings suggest
rapid lipid membrane turnover indicative of cellular inflammation
in basal ganglia and posterior gray matter without appreciable
change in metabolites referable to gliosis or neuronal injury.
Although it has been suggested that alterations in CHO/CR may
be reflective of change in brain volumes, it is not likely to reflect
atrophy in our work given the acute stage of disease in otherwise
healthy subjects [22]. The novelty of this finding relates to the very
early evaluation in humans; however, a limitation relates to other
potential factors that may influence the metabolic markers,
particularly methamphetamine use in some cases. Exclusion of
cases known to have active methamphetamine use at entry (n=2)
did not appreciably alter our findings; although significance
crossed 0.05 for Pillai’s trace on model 2 (to 0.0535). Based on
published work, gender should not have influenced metabolite
levels in the voxels studied despite differences noted in acute cases
(84% male) compared to controls (50% male, p=0.006). [23] We
also note comparison to healthy Thai controls and do not have
cases of non-virally induced neurological damage, limiting our
ability to focus attribution on viral mechanisms.
Unexpectedly, we noted a rise in NAA/CR in several brain
regions associated with treatment. Despite this finding, neither the
baseline nor the six-month NAA/CR ratios differed in the acute
compared to control groups. Recognizing the risk that the trend
could be an artifact of using CR as a standardizing metabolite, we
subsequently evaluated NAA concentrations (uncorrected for T1
and T2 relaxation times) at these voxels, confirming a rise of NAA
at BG but not at other locations. Since neither NAA nor NAA/CR
differed from that of control subjects at any time point, the clinical
significance of this finding may be less important and speculation
regarding etiology premature. Our study design was limited by
having control subjects imaged only once (baseline) with our
comparison to acute cases who were imaged longitudinally.
We did not identify a decrease in markers of neuronal injury in
early HIV. Our study subjects were imaged substantially earlier
than those included in a prior report demonstrating reduced
NAA/CR ratios in early infection in which subjects were enrolled
up to 90 days after Western blot evidence of infection [5].
Furthermore, our subjects were neurologically asymptomatic.
Simian models also have identified early neuronal injury by MRS;
but, these models employ neurovirulent viral strains and immune
depleted macaques, thus, may be less reflective of natural infection
in humans where mucosal infection results in viral selection
(transmitted viruses) and the inoculation may be smaller [24]. HIV
subtypes in U.S. studies are likely to be type B, whereas most
individuals in our Thai cohort are infected with a recombinant
form of A and E viruses (CRF AE_01), a factor that could
influence neurovirulence.
The differences observed in NAA/CR and GLX/CR between
acute and chronic groups is likely related to smaller bidirectional
alterations in both acute and chronic groups relative to the control
group, although, this is speculative since no statistically significant
differences to controls was identified in either group. In contrast, a
reduction of glutamate has been observed in cognitively normal
chronic HIV+subjects and in other studies of early HIV, but with
similar caveats that the timing was later than that accomplished in
our study, and effects of variable ART use cannot be excluded
[25,26]. Overall, these data suggest that NAA is not substantially
altered in very early HIV infection, providing theoretical evidence
for a potential window of opportunity where intervention may
preserve brain function, recognizing that identification of infection
this early in the clinical setting is challenging. Since all cases were
treated immediately upon detection, we cannot inform the
duration of this window.
Similar to our longitudinal CHO data, a small decrease in MI/
CR was noted in OGM after treatment. Here, however, neither
baseline nor follow-up values differed statistically from that of our
control group. Elevated MI has been observed in cognitively
impaired HIV+subjects during the chronic stage of infection [21].
Consistent with other reports investigating early infection, we did
not identify significant change in MI in acute HIV [5]. This likely
reflects that the processes in the CNS during acute HIV infection
do not include substantial gliosis [27].
Our observations support the hypothesis that immune cellular
infiltration and turnover characterizes the brain during the earliest
stage of HIV infection, providing an early conduit for brain
parenchymal viral seeding [28]. Added to knowledge that HIV
RNA is detected in CSF within the first week after infection, these
data are indirect evidence that the CNS viral reservoir may be
established within weeks of infection [3]. Our data inform
emerging intervention strategies designed to cure HIV that are
dependent on purging latent reservoirs. The broad distribution of
CHO/CR noted at baseline may suggest selective vulnerability.
This would have been more suggestive if the longitudinal values
were mixed; however, we saw a tendency for the individuals with
higher ratios at baseline to have higher ratios post-ART. Thus, the
distribution may represent background host variability.
In this work, the duration of HIV and Fiebig stage did not
appreciably predict levels of MRS metabolites. In FWM, CSF
HIV RNA level correlated to higher GLX/CR, but we did not
identify associations for any other voxel/metabolite pair. Togeth-
er, these findings suggest that the inflammation noted during acute
HIV is likely not dependent on the level of systemic antibody
response, and that CSF HIV RNA may correlate with release of
neurotoxins in the brain but otherwise is independent of brain
inflammation in this early period.
We had anticipated that the largest metabolic changes would be
seen in BG and FWM based on the known higher frequency of
detection of HIV antigen in these regions at autopsy in chronic
MR Spectroscopy during Acute HIV Infection
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and OGM, none were noted in FWM. This suggests that BG and
OGM have the highest degree of vulnerability for cellular
infiltration during acute HIV with BG but not OGM remaining
a site of high viral burden in chronic HIV. A recent report noted
grey matter atrophy with expansion of the third ventricle at one
year after infection [30]. Visual inspection of high-resolution T1-
weighted and T2-weighted structural images did not identify
abnormalities in our subjects.
In conclusion, this study identified indirect evidence for brain
parenchymal cellular infiltration in the absence of neuronal
dysfunction or gliosis during the first month following HIV
infection. We further found that this process is not present
following 6 months of ART initiated immediately after diagnosis.
Figure 2. Metabolites demonstrating change associated with antiretroviral treatment. Metabolites demonstrating change associated with
antiretroviral treatment included those demonstrating decreased inflammation [Panels A (MI/Cr in Occipital Grey Matter) and B (CHO/Cr in Basal
Ganglia)] and those demonstrating increased neuronal integrity [Panels C (NAA/Cr in Frontal Grey Matter), D (NAA/Cr in Frontal White Matter), and E
(NAA/Cr in Occipital Grey Matter)].
doi:10.1371/journal.pone.0049272.g002
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PLOS ONE | www.plosone.org 6 November 2012 | Volume 7 | Issue 11 | e49272Our findings highlight a potential pathway for early seeding of
HIV and initial steps toward establishment of latent viral reservoirs
in CNS, and suggest that early ART may be neuroprotective as a
means to prevent neuronal injury and ameliorate brain inflam-
mation.
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